Loading company
Immuneering Corp
IMRX · Nasdaq · ·
Next earnings: November 11, 2026
$4.14-0.5%Sep 29 close
- 1M
- -17.0%
- 6M
- -15.2%
- 1Y
- -40.9%
- 5Y
- -87.4%
IMRX · Nasdaq · ·
Next earnings: November 11, 2026
$4.14-0.5%Sep 29 close
Immuneering Corp is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2023, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2023 | 3 months toDec 31, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $455.00 | -100.00% |
| Profit | -$17.3M | -$14.4M | -19.65% |
| Profit per share | -$0.27 | -$0.40 | +32.50% |
| Free Cash Flow | -$16.5M | -$9.4M | -74.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Immuneering Corp’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Immuneering Corp has no earnings call transcript available.